Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

What is the Immune System?01:38

What is the Immune System?

Overview
Classification of Leukocytes01:30

Classification of Leukocytes

Leukocytes are classified into two groups based on the presence or absence of cytoplasmic granules. Granular leukocytes, which contain granules, belong to the myeloid lineage and are divided into three subtypes: neutrophils, eosinophils, and basophils. These cells are roughly spherical and characterized by the granules in their cytoplasm.
Neutrophils are the most abundant type of granular leukocytes, comprising 50-70% of all leukocytes. They feature small, evenly distributed granules and a...
Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
Rocky Mountain Spotted Fever01:26

Rocky Mountain Spotted Fever

Rocky Mountain Spotted Fever (RMSF) is a severe tick-borne illness caused by Rickettsia rickettsii, a Gram-negative, coccobacillary bacterium. This pathogen is an obligate intracellular parasite, requiring a host cell for replication. Transmission occurs through the bite of an infected tick. In the United States, the most important vectors are Dermacentor variabilis (American dog tick) and Dermacentor andersoni (Rocky Mountain wood tick), though other tick species may also serve as vectors.
Leishmaniasis01:30

Leishmaniasis

Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study.

The British journal of dermatology·2018
Same author

Repeated brain conventional MRI and SPECT evaluation in systemic lupus erythematosus patients with and without neuropsychiatric involvement: a follow up study.

Lupus·2011
Same author

Pregnancy in patients with undifferentiated connective tissue disease: a prospective case-control study.

Lupus·2011
Same author

Meningioma and systemic lupus erythematosus: a matter of pure coincidence?

Lupus·2009
Same author

Is there any role for tumour necrosis factor related apoptosis inducing ligand-osteoprotegerin (TRAIL-OPG) interaction in rheumatoid arthritis?

Annals of the rheumatic diseases·2008
Same author

Optimizing clinical monitoring of central nervous system involvement in SLE.

Autoimmunity reviews·2008
Same journal

Rethinking anticoagulation intensity during extracorporeal membrane oxygenation.

Lancet (London, England)·2026
Same journal

Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.

Lancet (London, England)·2026
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Ver todos los artículos relacionados
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: Jun 30, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

El lupus eritematoso sistémico es el lupus eritematoso sistémico.

G Ruiz-Irastorza1, M A Khamashta, G Castellino

  • 1Lupus Research Unit, Rayne Institute, St Thomas' Hospital, London, UK.

Lancet (London, England)
|April 11, 2001
PubMed
Resumen
Este resumen es generado por máquina.

Esta revisión pone de relieve los avances clínicos clave en el lupus eritematoso sistémico (LES) y el síndrome antifosfolípido (APS) de 1995-2000. Detalla los criterios actualizados, nuevos tratamientos como el micofenolato mofetil y mejores tasas de supervivencia de los pacientes.

Más Videos Relacionados

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

Murine Bilateral Renal Lymphadenectomy
06:31

Murine Bilateral Renal Lymphadenectomy

Published on: December 30, 2025

Videos de Experimentos Relacionados

Last Updated: Jun 30, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

Murine Bilateral Renal Lymphadenectomy
06:31

Murine Bilateral Renal Lymphadenectomy

Published on: December 30, 2025

Área de la Ciencia:

  • Reumatología Reumatología.
  • Inmunología Clínica Inmunología Clínica.

Sus antecedentes:

  • El lupus eritematoso sistémico (SLE) y el síndrome antifosfolípido (APS) son enfermedades autoinmunes complejas con un impacto clínico significativo.
  • Los avances en la comprensión y el manejo de estas condiciones son cruciales para mejorar los resultados de los pacientes.

Objetivo del estudio:

  • Revisar los principales avances clínicos en el LES y el SPA entre 1995 y 2000.
  • Resumir las actualizaciones en los criterios de clasificación, epidemiología y estrategias terapéuticas.

Principales métodos:

  • Revisión de la literatura de estudios clínicos publicados entre 1995 y 2000.
  • Análisis de ensayos controlados aleatorios y datos epidemiológicos.

Principales resultados:

  • Criterios de clasificación actualizados para SLE y APS.
  • Definición de 19 subconjuntos de lupus neuropsiquiátrico.
  • Aumento de la incidencia y las tasas de supervivencia de los pacientes con LES.
  • Las funciones establecidas para la ciclofosfamida, el metotrexato, los antipalúdicos y la terapia hormonal.
  • Datos emergentes sobre la ciclosporina y la talidomida.
  • Aumento del uso de micofenolato de mofetil y trasplante de células madre para casos refractarios.
  • Nuevos conocimientos sobre el manejo de la trombosis en el SPA y los embarazos de alto riesgo en el LES/SPA.

Conclusiones:

  • Entre 1995 y 2000 se produjeron avances significativos en la gestión del LES y del SPA.
  • Se ampliaron las opciones terapéuticas, incluyendo nuevos agentes y el trasplante de células madre.
  • Una mejor comprensión de los subconjuntos de enfermedades y las tendencias epidemiológicas informó la práctica clínica.